3-Benzyl-1,3-oxazolidin-2-ones as mGluR2 positive allosteric modulators: Hit-to lead and lead optimization

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 9, 2009, Pages 2524-2529

  Duplantier, Allen J ^a   Efremov, Ivan ^a   Candler, John ^a   Doran, Angela C ^a   Ganong, Alan H ^a   Haas, Jessica A ^a   Hanks, Ashley N ^a   Kraus, Kenneth G ^a   Lazzaro Jr , John T ^a   Lu, Jiemin ^a   Maklad, Noha ^a   McCarthy, Sheryl A ^a   O'Sullivan, Theresa J ^a   Rogers, Bruce N ^a   Siuciak, Judith A ^a   Spracklin, Douglas K ^a   Zhang, Lei ^a  

^a PFIZER INC   (United States)

Author keywords

Carbamate; mGluR2; Positive allosteric modulator; Schizophrenia

Indexed keywords

EGLUMETAD; METABOTROPIC RECEPTOR 2; OXAZOLIDINE DERIVATIVE;

ALLOSTERISM; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; MICROSOME MEMBRANE; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; RAT; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ALLOSTERIC REGULATION; ALLOSTERIC SITE; CARBAMATES; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; HUMANS; INHIBITORY CONCENTRATION 50; LIGANDS; MICROSOMES; MODELS, CHEMICAL; MOLECULAR STRUCTURE; OXAZOLIDINONES; RECEPTORS, METABOTROPIC GLUTAMATE; SCHIZOPHRENIA;

EID: 64249109525     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.03.032     Document Type: Article

References (30)

1. Pin J.-P., Galvez T., and Prezeau L. Pharmacol. Ther. 98 (2003) 325
2. Poisik O., Raju D.V., Verreault M., Rodriguez A., Abeniyi O.A., Conn P.J., and Smith Y. Neuropharmacology 49 (2005) 57
3. Kew J.N.C., and Kemp J.A. Psychopharmacology 179 (2005) 4
4. Grillon C., Cordova J., and Levine L.R. Psychopharmacology 168 (2003) 446
5. Rorick-Kehn L.M., Johnson B.G., Knitowski K.M., Salhoff C.R., Witkin J.M., Perry K.W., Griffey K.I., Tizzano J.P., Monn J.A., McKinzie D.L., and Schoepp D.D. Psychopharmacology 193 (2007) 121
6. Marek G.J. Curr. Opin. Pharmacol. 4 (2004) 18
7. Linden A.-M., and Schoepp D.D. Drug Discovery Today: Therapeutic Strategies 3 4 (2006) 507
8. Patil S.T., Zhang L., Martenyi F., Lowe S.L., Jackson K.A., Andreev B.V., Avedisova A.S., Bardenstein L.M., Gurovich I.Y., Morozova M.A., Mosolov S.N., Neznanov N.G., Reznik A.M., Smulevich A.B., Tochilov V.A., Johnson B.G., Monn J.A., and Schoepp D.D. Nat. Med. 13 (2007) 1102
9. For a review, see:. Rudd M.T., and McCauley J.A. Curr. Top. Med. Chem. 5 (2005) 869
10. Zhang L., Rogers B.N., Duplantier A.J., McHardy S.F., Efremov I., Berke H., Qian W., Zhang A.Q., Maklad N., Candler J., Doran A.C., Lazzaro Jr. J.T., and Ganong A.H. Bioorg. Med. Chem. Lett. 18 (2008) 5493
11. Recasens M., Guiramand J., Aimar R., Abdulkarium A., and Barbanel G. Curr. Drug Targets 8 (2007) 651
12. Gjoni T., and Urwyler S. Neuropharmacology 55 (2008) 1293
13. Goodnow Jr. R.A., and Gillespie P. Prog. Med. Chem. 45 (2007) 1
14. Wunberg T., Hendrix M., Hillisch A., Lobell M., Meier H., Schmeck C., Wild H., and Hinzen B. Drug Discovery Today 11 (2006) 175
15. Keseru G., and Makara G. Drug Discovery Today 11 (2006) 741
16. Alanine A., Nettekoven M., Roberts E., and Thomas A.W. Comb. Chem. High Throughput Screen. 6 (2003) 51
17. MS-based quantification of the basal/apical transfer rate of a test compound at 2 μM across contiguous monolayers from MDCK (Madin Darby Canine Kidney) cells.
18. Ratio from the MS-based quantification of apical/basal and basal/apical transfer rates of a test compound at 2 μM across contiguous monolayers from MDR1-transfected MDCK cells.
19. Hopkins A.L., Groom C.R., and Alexander A. Drug Discovery Today 9 (2004) 430
20. 50 value depends on the concentration of glutamate present in the assay, the precise assessment of the ligand efficiency based on this assay was not possible. At the same time, comparison of LE profiles of multiple chemotypes using the same mGluR2 assay provided a valuable perspective when assessing lead generation potential of different chemical series.
21. Hitchcock S.A. Curr. Opin. Chem. Biol. 12 (2008) 318
22. Patel Y., Gillet V.J., Howe T., Pastor J., Oyarzabal J., and Willett P. J. Med. Chem. 51 (2008) 7552
23. Dill K.A. J. Biol. Chem. 272 (1997) 701
24. Feng B., Mills J.B., Davidson R.E., Mireles R.J., Janiszewski J.S., Troutman M.D., and de Morais S.M. Drug Metab. Dispos. 36 (2008) 268
25. Fluorescence-based measurement of CYP inhibition by incubating the recombinant CYP (Cytochrome P450) with a test compound and the corresponding fluorescent probe at 3 μM.
26. 3H-dofetilide binding to membranes from hERG-expressing HEK cells at 10 μM.
27. In efforts to obtain analogs in solid form, we compared the MPs of small alkoxyphenyl ethers (oils) to benzylphenyl ether (∼40 °C), phenyl ether (∼28 °C) and biphenyl (∼70 °C).
28. Hirota S., Kawashima N., Chaki S., and Okuyama S. CNS Drug Rev. 9 4 (2003) 375
29. Satow A., Maehara S., Ise S., Hikichi H., Fukushima M., Suzuki G., Kimura T., Tanaka T., Ito S., Kawamoto H., and Ohta H. J. Pharmacol. Exp. Ther. 326 (2008) 577
30. Gonzalez-Maeso J., Ang R.L., Yuen T., Chan P., Weisstaub N.V., Lopez-Gimenez J.F., Zhou M., Okawa Y., Callado L.F., Milligan G., Gingrich J.A., Filizola M., Meana J.J., and Sealfon S.C. Nat. Lett. (2008) 1